Genmark Diagnostics Stock

Genmark Diagnostics EV/FCF

Delisted

The EV/FCF (Enterprise Value to Free Cash Flow) of Genmark Diagnostics (GNMK) as of Jul 26, 2026 is -147.08. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -48.22 — a change of 205.05% (lower).

EV/FCF

-147.08

YoY

205.05%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Genmark Diagnostics is 2026 -147.08 . EV/FCF (Enterprise Value to Free Cash Flow) of Genmark Diagnostics was 2025 -48.22 . It decreases by 205.05% lower compared to the previous year.
Access this data via the Eulerpool API

Genmark Diagnostics Stock analysis

What does Genmark Diagnostics do? The company Genmark Diagnostics was founded in 1999 in California, USA. Its goal is to develop and produce diagnostic and testing solutions for the medical and biotechnology industries, with a focus on microfluidic technology. The company offers comprehensive services from the development of diagnostic and testing solutions to the production of devices and systems. Its main business areas are molecular diagnostics, laboratory test automation, and genomics. Genmark Diagnostics provides a variety of test solutions for diseases in the field of molecular diagnostics, as well as automation platforms for laboratory testing and products for genomic analysis. The company's products, such as the ePlex® system, aim to improve the accuracy and speed of medical diagnostics. Genmark Diagnostics is headquartered in Carlsbad, California, USA and has international branches. Its mission is to enhance the accuracy and speed of medical diagnostics worldwide through innovative devices and systems. Genmark Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmark Diagnostics stock

EV/FCF (Enterprise Value to Free Cash Flow) of Genmark Diagnostics is -147.08 in 2026.

Access this data via the Eulerpool API

Valuation — Genmark Diagnostics

All Key Metrics — Genmark Diagnostics